NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies

06 Aug 2021 (Last Updated August 6th, 2021 07:37)

The Phase III part of the ACTIV-2 trial is assessing symptomatic Covid-19 patients with a greater risk of disease progression.

NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies
Colourised scanning electron micrograph of a cell (brown) infected with SARS-CoV-2 virus particles (blue). Credit: NIAID.

Brii Biosciences has reported that the National Institutes of Health (NIH)’s ACTIV-2 clinical trial in the US completed enrolment for the Phase III part assessing its combination treatment, BRII-196 plus BRII-198, for Covid-19.

Obtained from convalesced Covid-19 patients, BRII-196 and BRII-198 are non-competing monoclonal antibodies that neutralise SARS-CoV-2.

Funded by the NIH unit National Institute of Allergy and Infectious Diseases (NIAID), the randomised, blinded, controlled adaptive platform ACTIV-2 master protocol is led by the NIAID-sponsored AIDS Clinical Trials Group.

The trial is analysing the safety and efficacy of various experimental drugs for symptomatic Covid-19 treatment in non-hospitalised adults.

In January this year, the NIH initiated the Phase II/III ACTIV-2 trial of Brii Biosciences’ combination therapy.

The Phase III part of the trial will assess the combination treatment in 846 outpatients enrolled at centres in the US, Brazil, South Africa, Mexico and Argentina.

Subjects with symptomatic Covid-19 who are at increased risk of clinical progression are part of the trial.

The combined primary goal of the trial is to evaluate hospitalisations and death in the treatment arm as against placebo following 28 days of therapy.

The progression to the Phase III part comes after the combination met pre-defined, study-defined safety and efficacy goals in the Phase II segment.

After the conclusion of the trial, ACTIV-2 dataset analysis will comprise subjects enrolled between January and July this year, a period when a quick emergence of new SARS-CoV-2 variants was observed worldwide.

Bri Biosciences added that clinical efficacy results of the combination therapy by variant type will be assessed as part of the analysis.

So far, the BRII-196 plus BRII-198 combination was observed to be generally safe and well-tolerated in Phase I and Phase II trials.

Furthermore, the combination demonstrated activity against key SARS-CoV-2 variants of concern, including Alpha, Beta, Gamma, Epsilon and Delta variants during in vitro pseudovirus testing.

A Phase II trial of the combination treatment is underway in China.

In March last year, Brii Biosciences signed a memorandum of understanding with Columbia University to provide funding for research on solutions to treat, prevent and diagnose coronaviruses, including Covid-19.